Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease

• Status: Recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This research study is designed to investigate a new potential medicine for mobilizing stem cells and apheresis collection in patients with Sickle Cell Disease. MGTA-145, the new potential medicine, will be given with plerixafor.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Magenta Therapeutics, Inc.
• Collaborator: bluebird bio
• Treatments: Plerixafor

Criteria

Inclusion Criteria:

• Subject must be ≥18 to ≤35 years of age.

• Subject must weigh ≥30 kg.

• Subject must have a diagnosis of Sickle Cell Disease.

Exclusion Criteria:

• Subject must not have had a vaso-occlusive event (VOE) requiring a visit to a healthcare facility within 30 days of screening.

• Subject must not have undergone or attempted and failed previous hematopoietic stem cell (HSC) collection.

• Subject must not have had a prior autologous or allogeneic transplantation, inclusive of gene therapy.

• Male subject must be willing or able to use a highly effective method of contraception for 3 months during and after treatment.

• Female subject must not be pregnant or breastfeeding. If sexually active, female subject must be willing or able to use a highly effective method of contraception for 3 months during and after treatment.